Machine learning-based diagnostics startup Dascena Inc. has won the U.S. FDA’s breakthrough device designation for its Previse algorithm, which is designed to predict acute kidney injury (AKI) before clinical symptoms. In early validation tests, Previse detected AKI more than a day before patients exhibited kidney damage or impaired function.
LONDON – AM-Pharma BV raised a further $52 million for the phase III trial of its recombinant alkaline phosphatase product, Recap, in treating sepsis-associated acute kidney injury (AKI), but now faces a delay in starting the study, as the COVID-19 crisis takes up more and more clinical resources.
HONG KONG – Yokneam, Israel-based Serenno Medical Ltd. has unveiled a device for automatic monitoring and detection of kidney damage in patients. Known as Sentinel, the device is a continuous urine output (UO) monitor that measures urine flow rate and volume in real time.
LONDON – AM-Pharma BV has raised €116 million (US$130.7 million) in a series E round to fund phase III development of its recombinant alkaline phosphatase, Recap, in the treatment of sepsis-associated acute kidney injury (SA-AKI).